Left Atrial Appendage Occlusion Devices Versus Pharmacological Agents for Stroke Prevention in Atrial Fibrillation  by Messori, Andrea & Trippoli, Sabrina
Letters J A C C V O L . 6 6 , N O . 1 8 , 2 0 1 5
N O V E M B E R 3 , 2 0 1 5 : 2 0 5 2 – 8
2056Raj Ganeshan, MD
Brian Malm, MD
*John Concato, MD, MS, MPH
*Yale University School of Medicine
Veterans Affairs Connecticut Healthcare System
Clinical Epidemiology Research Center
950 Campbell Avenue (Mailcode 151B)
West Haven, Connecticut 06516
E-mail: john.concato@yale.edu
http://dx.doi.org/10.1016/j.jacc.2015.06.1357
Please note: The authors have reported that they have no relationships relevant
to the contents of this paper to disclose. P.K. Shah, MD, served as Guest Editor
for this paper.
RE F E RENCE
1. Yeh RW, Kereiakes DJ, Steg PG, et al. Beneﬁts and risks of extended
duration dual antiplatelet therapy after PCI in patients with and without acute
myocardial infarction. J Am Coll Cardiol 2015;65:2211–21.REPLY: Analysis of Dual Antiplatelet TherapyWe thank Dr. Ganeshan and colleagues for their in-
terest in our paper (1). In our subgroup analysis of the
DAPT Study (Dual Antiplatelet Therapy Study) (1),
continued thienopyridine therapy beyond 12 months
after coronary stent placement provided consistent
reductions in ischemic endpoints while increasing
bleeding in patients presenting initially with or
without myocardial infarction. Although not included
in our original publication, we have performed the
sensitivity analysis requested by Ganeshan and col-
leagues, grouping unstable angina patients with
myocardial infarction patients (acute coronary syn-
drome [ACS] group). In this analysis, consistent re-
ductions in ischemic endpoints were again observed
with continued thienopyridine in both ACS and non-
ACS patients (ACS group: stent thrombosis hazard
ratio [HR]: 0.35; p < 0.001, myocardial infarction HR:
0.47; p < 0.001; non-ACS group: stent thrombosis HR:
0.25, p < 0.001, myocardial infarction HR: 0.61;
p ¼ 0.002; interaction p ¼ NS for both comparisons).
GUSTO (Global Utilization of Streptokinase and Tis-
sue Plasminogen Activator for Occluded Coronary
Arteries) moderate or severe bleeding was increased
with continued thienopyridine in both groups as well
(ACS group HR: 2.01; p ¼ 0.002; non-ACS group HR:
1.49; p ¼ 0.024; interaction p ¼ 0.31).
As Dr. Ganeshan and colleagues rightly point out,
our study was a post-hoc subgroup analysis of a
completed randomized clinical trial (2,3) and was not
speciﬁcally powered to assess the interactions pre-
sented. Its conclusions should be interpreted with
this in mind.A large fraction of eligible patients were not ran-
domized in the DAPT study, primarily due to patient
and provider preference. Among myocardial infarc-
tion patients, those who were eligible, but not ran-
domized, were similar in age, but were more often
women (38.3% vs. 31.8%; p < 0.001), nonwhite (12.7%
vs. 8.4%), and had higher rates of diabetes, prior
stroke, congestive heart failure, and prior coronary
revascularization (p < 0.001 for each), as compared
with those randomized in the study. Similar results
were observed among patients without myocardial
infarction. These ﬁndings suggest that the random-
ized patients were somewhat lower risk for recurrent
ischemic events than those who were enrolled. It is
likely that had these eligible subjects also been ran-
domized, a treatment effect of the same magnitude or
larger would have been observed.Robert W. Yeh, MD, MSc
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Occlusion Devices Versus
Pharmacological Agents
for Stroke Prevention in
Atrial FibrillationIn evaluating the effectiveness of the Watchman
appendage occlusion device (AOD) in patients with
FIGURE 1 Comparison of AOD Versus NOACs Evaluated According to the Endpoint of
Stroke or Systemic Embolism in Patients With Atrial Fibrillation
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The ﬁgure separately shows the forest plot for the analyses based on 2 different datasets
for Watchman (2014 dataset: 1,107 patients [blue]; 2015 dataset: 2,406 patients [orange]);
the data of NAOCs are instead the same for the 2 analyses. In both datasets, the horizontal
bars indicate the 2-sided 95% CI for the RD (solid square) whereas the noninferiority test is
applied based on the vertical dotted line, that reﬂects the pre-determined noninferiority
margin (at þ2.5% [5]). The criterion for demonstrating noninferiority (alpha level ¼ 2.5%)
is when the “right” extreme of the 95% CI does not cross the vertical dotted line. AOD ¼
atrial appendage occlusion device; CI ¼ conﬁdence interval; NOAC ¼ novel oral anticoag-
ulant; RD ¼ risk difference.
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Holmes et al. (1) is represented by the large popula-
tion of patients included in the analysis (which tends
to approximate the totality of evidence). The authors
necessarily designed their study of effectiveness
(endpoint: stroke or systemic embolism) by com-
paring AOD with warfarin because this com-
parison reﬂected the available clinical material or, at
least, that resulting from the randomized trials.
Consequently, the results expressing the comparison
between AOD and warfarin is the key message
conveyed by their study.
In discussing their results, however, Holmes
et al. (1) pointed out that novel oral anticoagulants
(NOACs) also currently represent a treatment option
indicated for these patients, but no data of (direct)
clinical comparison are available for AOD versus
NOACs, and so this question remains open.
Despite their well-known limitations, indirect
comparisons can be useful to explore a therapeutic
question on which no direct comparative data are
available (2,3). In 2014, we carried out one such in-
direct comparison between AOD and NOACs (3), at a
time when the published population of patients
treated with Watchman was relatively small (data
from 1,107 patients published by Bajaj et al. [2]).
The study by Holmes et al. (1) now offers a much
larger population (n ¼ 2,406) for performing this in-
direct comparison. Hence, in the analysis presented
herein, we have updated our previous results pub-
lished in 2014 (3), and we have redetermined this
indirect comparison between AOD and NOACs by
including the data of the patient-level meta-analysis
by Holmes et al. (1).
Figure 1 shows the results of this re-analysis (the
ﬁgure includes a noninferiority margin that reﬂects
the same margin adopted in the randomized trials
[5]). Firstly, it appears that the effectiveness data
published in 2014 for Watchman (event rate ¼ 0.99%
[4]) were more favorable to the device than those
published by Holmes et al. (1) (event rate ¼ 2.72%).
Despite this, the overall message resulting from this
noninferiority analysis is that for both datasets, the
effectiveness of Watchman fully satisﬁes the non-
inferiority criterion. In fact, the upper limit of the
conﬁdence interval (CI) of Watchman (see Figure 1)
remains well within the “right” noninferiority margin
(i.e., remains “on the left” of the margin without
intercepting the margin itself), thus satisfying the
noninferiority criterion (i.e., AOD is noninferior to
NOACs). This ﬁnding represents the main result of
our reanalysis.
However, it should also be noted that in Figure 1,
the right margin of the CI for AOD also remained onthe left of the line of identity (although to a minimal
extent); this suggests that the superiority of AOD
versus NOACs could also be the conclusion from these
data.
It should be pointed out that these indirect ana-
lyses are largely speculative, and so caution should be
exercised in drawing any conclusion from these data.
Despite this, the (indirect) evidence resulting from
the present reanalysis does support the hypothesis
that AOD is noninferior to NOACs.*Andrea Messori, PharmD
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Devices Versus Pharmacological Agents for
Stroke Prevention in Atrial FibrillationWe thank Drs. Messori and Trippoli for their com-
ments on our paper (1). They importantly highlight
the issue that the only 2 randomized trials in the
ﬁeld of left atrial appendage occlusion used warfarin
as the control value. Both randomized trials, PRO-
TECT AF (WATCHMAN Left Atrial Appendage System
for Embolic PROTECTion in Patients With Atrial
Fibrillation) (2) and PREVAIL (Watchman LAA
Closure Device in Patients With Atrial Fibrillation
Versus Long Term Warfarin Therapy) (3), compared
the Watchman device (Boston Scientiﬁc, Marl-
borough, Massachusetts) versus a control arm of
warfarin. The PROTECT AF trial had been planned
when warfarin was the most commonly used anti-
coagulant agent. Subsequently, several novel oral
anticoagulant agent (NOACS) have now been tested
versus warfarin for stroke prevention in the setting
of nonvalvular atrial ﬁbrillation.
Important questions remain, including what
would be the result of a randomized trial of
Watchman versus any one of the NOACS? No ran-
domized trial is available. Messori et al. (4) have
advanced the ﬁeld using an indirect comparisonapproach on the basis of a speciﬁc noninferiority
margin that had been used in other randomized trials
in the ﬁeld of NOACs versus warfarin. Initially pub-
lished in 2013, they have updated data in this current
letter (Figure 1 of Holmes Jr. [1]). In this indirect
comparison analysis, the “effectiveness of Watchman
fully satisﬁes the noninferiority criteria” of device
versus NOAC and even suggests superiority.
These ﬁndings are very important, interesting, and
exciting. We agree, however, with Dr. Messori and
colleagues that these “indirect analysis are largely
speculative”; they need to be replicated in more
robust scientiﬁc studies. This analysis, however, does
offer the potential that the role of left atrial
appendage occlusion devices will increase even in the
face of availability of new anticoagulant regimens.*David R. Holmes, Jr., MD
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